ClinicalTrials.gg
Active, not recruitingNCT05160922Updated Mar 30, 2026

Crizotinib Continuation Clinical Study

A Phase 4 interventional study of crizotinib in NSCLC, ALCL and IMT, sponsored by Pfizer. Active, not recruiting at 13 sites in 5 countries. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
0 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 6 under way, 1 of them phase 3. Crizotinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
17th of 23
27 · median 80
Started
2021
with 1 other
Phase 4
Only one
of the 23
Registered
22nd of 23
by date
Lead sponsor
9 of 23
Pfizer

Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by enrollment, is one of 2 that started in 2021, is the only one in phase 4, and was the 22nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About crizotinib

Crizotinib: first FDA approval 2011 (XALKORI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 0 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.

Read the detailed description

Participants not previously enrolled or who have discontinued study treatment or safety follow-up in a current Pfizer sponsored crizotinib clinical study are not eligible for participation in this continuation study.

03

Conditions studied

  • NSCLC
  • ALCL
  • IMT

Keywords

  • crizotinib
  • Xalkori
  • Anaplastic Lymphoma Kinase
  • ALK
  • ROS1
  • NSCLC
  • Non-small Cell Lung Cancer
  • ALCL
  • anaplastic large cell lymphoma
  • IMT
  • inflammatory myofibroblastic tumour
04

Who can participate

Ages eligible
0 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participants must meet the following key inclusion criteria to be eligible for enrollment into the study:

  1. Any participant who is receiving crizotinib and deriving clinical benefit (as determined by their doctor) in a Crizotinib Study which is planned to close.
  2. Participants must agree to follow the reproductive criteria as outlined in protocol.
  3. No ongoing Grade ≥3 or intolerable Grade 2 AEs considered to be related to crizotinib treatment, except for those laboratory eligibility criteria described in Inclusion #4.
  4. Adult Participants (≥18 years): Adequate hepatic and bone marrow function. Stable renal function for at least 14 days.

Pediatric Participants (\<18 years): Adequate hepatic and bone marrow function. Stable renal function for at least 14 days.

Exclusion Criteria

Participants with any of the following characteristics/conditions will be excluded:

  1. Female participants who are pregnant or breastfeeding.
  2. Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Other
    crizotinib

    crizotinib oral treatment

    Drug: crizotinib

Interventions

  • crizotinib oral treatment

    Also known as: XALKORI

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events leading to permanent discontinuation of study intervention

    Safety data collection in this study will permit further characterization of the safety profile of crizotinib.

    Time frame: Baseline up to approximately 5 years

  2. Number of serious adverse events reported for all participants

    Safety data collection in this study will permit further characterization of the safety profile of crizotinib.

    Time frame: Baseline up to approximately 5 years

07

Study locations

13 sites
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Mar 2028, 74 months after the start.

Of 43 phase 4 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's planned 74 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2021
First posted
Dec 16, 2021
StartActual
Dec 27, 2021
Primary completionEst.
Mar 21, 2028
CompletionEst.
Mar 21, 2028
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05160922
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 16, 2021
Start date
Dec 27, 2021
Primary completion
Mar 21, 2028 (estimated)
Completion
Mar 21, 2028 (estimated)
Last update
Mar 30, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crizotinib

Start the discussion